Department of Autoimmune Diseases, ICMiD, Hospital Clínic, and Department of Medicine, University of Barcelona, Barcelona, Spain (M.R.).
Department of Medicine, University of Barcelona; Primary Healthcare Transversal Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Primary Care Centre Les Corts, Consorci d'Atenció Primària de Salut Barcelona Esquerra (CAPSBE), Barcelona, Spain (A.S.).
Ann Intern Med. 2024 Feb;177(2):ITC17-ITC32. doi: 10.7326/AITC202402200. Epub 2024 Feb 13.
Immune-related adverse events (irAEs) are toxicities that arise after the administration of monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) in patients with cancer. They can occur at any time after initiation of ICI treatment, with a broad clinical phenotype that can be organ-specific or systemic. Although most irAEs manifest as mild to moderate signs and symptoms, severe forms of irAEs can lead to irreversible organ failure and have acute life-threatening presentations. Treatment should be tailored to the specific organ involved and the severity. Glucocorticoids are the first-line treatment for most irAEs, with immunosuppressants and biologics mainly used as second-line treatments.
免疫相关不良反应（irAEs）是在癌症患者接受免疫检查点单克隆抗体（免疫检查点抑制剂 [ICI]）治疗后出现的毒性反应。它们可能在开始 ICI 治疗后的任何时间发生，具有广泛的临床表型，可以是器官特异性的或全身性的。虽然大多数 irAEs 表现为轻度至中度的体征和症状，但严重的 irAEs 可导致不可逆转的器官衰竭，并具有急性危及生命的表现。治疗应根据具体受累器官和严重程度进行调整。糖皮质激素是大多数 irAEs 的一线治疗药物，免疫抑制剂和生物制剂主要用作二线治疗药物。
